{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:19:04Z","timestamp":1707524344860},"reference-count":39,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,14]]},"DOI":"10.7759\/cureus.17978","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T03:10:15Z","timestamp":1631675415000},"source":"Crossref","is-referenced-by-count":0,"title":["Synergistic Effects of Psychotropics Leading to Extraordinary Weight Gain"],"prefix":"10.7759","author":[{"given":"Allyson J","family":"Kemp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sana E","family":"Kazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James L","family":"Megna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubov V","family":"Leontieva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Prevalence of obesity and severe obesity among adults: United States, 2017-2018","volume":"(360)","author":"Hales CM","year":"2020","unstructured":"Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017-2018. NCHS Data Brief. 2020, (360):1-8.","journal-title":"NCHS Data Brief"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/acer.12516","article-title":"Overweight and obesity among children and adolescents with fetal alcohol spectrum disorders","volume":"38","author":"Fuglestad AJ","year":"2014","unstructured":"Fuglestad AJ, Boys CJ, Chang PN, et al.. Overweight and obesity among children and adolescents with fetal alcohol spectrum disorders. Alcohol Clin Exp Res. 2014, 38:2502-8. 10.1111\/acer.12516","journal-title":"Alcohol Clin Exp Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.dhjo.2015.12.003","article-title":"Intellectual disability is associated with increased risk for obesity in a nationally representative sample of U.S. children","volume":"9","author":"Segal M","year":"2016","unstructured":"Segal M, Eliasziw M, Phillips S, et al.. Intellectual disability is associated with increased risk for obesity in a nationally representative sample of U.S. children. Disabil Health J. 2016, 9:392-8. 10.1016\/j.dhjo.2015.12.003","journal-title":"Disabil Health J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2008.03.070207","article-title":"Overweight and obese prevalence rates in African American and Hispanic children: an analysis of data from the 2003-2004 National Survey of Children's Health","volume":"21","author":"Lutfiyya MN","year":"2008","unstructured":"Lutfiyya MN, Garcia R, Dankwa CM, Young T, Lipsky MS. Overweight and obese prevalence rates in African American and Hispanic children: an analysis of data from the 2003-2004 National Survey of Children's Health. J Am Board Fam Med. 2008, 21:191-9. 10.3122\/jabfm.2008.03.070207","journal-title":"J Am Board Fam Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2020.112964","article-title":"Adverse childhood experiences and adult obesity: a systematic review of plausible mechanisms and meta-analysis of cross-sectional studies","volume":"223","author":"Wiss DA","year":"2020","unstructured":"Wiss DA, Brewerton TD. Adverse childhood experiences and adult obesity: a systematic review of plausible mechanisms and meta-analysis of cross-sectional studies. Physiol Behav. 2020, 223:112964. 10.1016\/j.physbeh.2020.112964","journal-title":"Physiol Behav"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-019-1498-1","article-title":"Socioeconomic deprivation, adverse childhood experiences and medical disorders in adulthood: mechanisms and associations","volume":"56","author":"Morris G","year":"2019","unstructured":"Morris G, Berk M, Maes M, Carvalho AF, Puri BK. Socioeconomic deprivation, adverse childhood experiences and medical disorders in adulthood: mechanisms and associations. Mol Neurobiol. 2019, 56:5866-90. 10.1007\/s12035-019-1498-1","journal-title":"Mol Neurobiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094112","article-title":"Almost all antipsychotics result in weight gain: a meta-analysis","volume":"9","author":"Bak M","year":"2014","unstructured":"Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One. 2014, 9:e94112. 10.1371\/journal.pone.0094112","journal-title":"PLoS One"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000161501.65890.22","article-title":"Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders","volume":"25","author":"Kinon BJ","year":"2005","unstructured":"Kinon BJ, Kaiser CJ, Ahmed S, Rotelli MD, Kollack-Walker S. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol. 2005, 25:255-8. 10.1097\/01.jcp.0000161501.65890.22","journal-title":"J Clin Psychopharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","volume":"123","author":"Rummel-Kluge C","year":"2010","unstructured":"Rummel-Kluge C, Komossa K, Schwarz S, et al.. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010, 123:225-33. 10.1016\/j.schres.2010.07.012","journal-title":"Schizophr Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2000.10.259","article-title":"Risperidone-associated weight gain in children and adolescents: a retrospective chart review","volume":"10","author":"Martin A","year":"2000","unstructured":"Martin A, Landau J, Leebens P, Ulizio K, Cicchetti D, Scahill L, Leckman JF. Risperidone-associated weight gain in children and adolescents: a retrospective chart review. J Child Adolesc Psychopharmacol. 2000, 10:259-68. 10.1089\/cap.2000.10.259","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-013-0016-6","article-title":"Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis","volume":"15","author":"Almandil NB","year":"2013","unstructured":"Almandil NB, Liu Y, Murray ML, Besag FM, Aitchison KJ, Wong IC. Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis. Paediatr Drugs. 2013, 15:139-50. 10.1007\/s40272-013-0016-6","journal-title":"Paediatr Drugs"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2008.09.025","article-title":"Weight effects associated with antipsychotics: a comprehensive database analysis","volume":"110","author":"Parsons B","year":"2009","unstructured":"Parsons B, Allison DB, Loebel A, Williams K, Giller E, Romano S, Siu C. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res. 2009, 110:103-10. 10.1016\/j.schres.2008.09.025","journal-title":"Schizophr Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300023","article-title":"Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia","volume":"28","author":"Casey DE","year":"2003","unstructured":"Casey DE, Daniel DG, Wassef AA, Tracy KA, Wozniak P, Sommerville KW. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology. 2003, 28:182-92. 10.1038\/sj.npp.1300023","journal-title":"Neuropsychopharmacology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-789X.2010.00800.x","article-title":"Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications","volume":"12","author":"Verrotti A","year":"2011","unstructured":"Verrotti A, D'Egidio C, Mohn A, Coppola G, Chiarelli F. Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. Obes Rev. 2011, 12:e32-43. 10.1111\/j.1467-789X.2010.00800.x","journal-title":"Obes Rev"},{"key":"ref15","article-title":"How to control weight gain when prescribing antidepressants: ignoring this side effect can increase medical risk, treatment nonadherence","volume":"6","author":"Schwartz T","year":"2007","unstructured":"Schwartz T, Meszaros Z, Khan R, et al.. How to control weight gain when prescribing antidepressants: ignoring this side effect can increase medical risk, treatment nonadherence. Current. 2007, 6:43.","journal-title":"Current"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbw058","article-title":"Pharmacogenetic associations of antipsychotic drug-related weight gain: a systematic review and meta-analysis","volume":"42","author":"Zhang JP","year":"2016","unstructured":"Zhang JP, Lencz T, Zhang RX, et al.. Pharmacogenetic associations of antipsychotic drug-related weight gain: a systematic review and meta-analysis. Schizophr Bull. 2016, 42:1418-37. 10.1093\/schbul\/sbw058","journal-title":"Schizophr Bull"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2016.11.056","article-title":"Insight gained from genome-wide interaction and enrichment analysis on weight gain during citalopram treatment","volume":"637","author":"Corfitsen HT","year":"2017","unstructured":"Corfitsen HT, Drago A. Insight gained from genome-wide interaction and enrichment analysis on weight gain during citalopram treatment. Neurosci Lett. 2017, 637:38-43. 10.1016\/j.neulet.2016.11.056","journal-title":"Neurosci Lett"},{"key":"ref18","article-title":"Interactions between the cytochrome P450 system and the second-generation antipsychotics","volume":"28","author":"Prior TI","year":"2003","unstructured":"Prior TI, Baker GB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci. 2003, 28:99-112.","journal-title":"J Psychiatry Neurosci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5545.192016","article-title":"Olanzapine has better efficacy compared to risperidone for treatment of negative symptoms in schizophrenia","volume":"58","author":"Suresh Kumar PN","year":"2016","unstructured":"Suresh Kumar PN, Anish PK, Rajmohan V. Olanzapine has better efficacy compared to risperidone for treatment of negative symptoms in schizophrenia. Indian J Psychiatry. 2016, 58:311-6. 10.4103\/0019-5545.192016","journal-title":"Indian J Psychiatry"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e328346063f","article-title":"PharmGKB summary: citalopram pharmacokinetics pathway","volume":"21","author":"Sangkuhl K","year":"2011","unstructured":"Sangkuhl K, Klein TE, Altman RB. PharmGKB summary: citalopram pharmacokinetics pathway. Pharmacogenet Genomics. 2011, 21:769-72. 10.1097\/FPC.0b013e328346063f","journal-title":"Pharmacogenet Genomics"},{"key":"ref21","doi-asserted-by":"crossref","DOI":"10.1097\/00002826-200003000-00006","article-title":"Neuropharmacology of paradoxic weight gain with selective serotonin reuptake inhibitors","volume":"23","author":"Harvey BH","year":"2000","unstructured":"Harvey BH, Bouwer CD. Neuropharmacology of paradoxic weight gain with selective serotonin reuptake inhibitors. Clin Neuropharmacol. 2000, 23:90-7.","journal-title":"Clin Neuropharmacol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2014.08.065","article-title":"Serotonin controlling feeding and satiety","volume":"277","author":"Voigt JP","year":"2015","unstructured":"Voigt JP, Fink H. Serotonin controlling feeding and satiety. Behav Brain Res. 2015, 277:14-31. 10.1016\/j.bbr.2014.08.065","journal-title":"Behav Brain Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-019-1346-1","article-title":"The effects of antipsychotic medications on microbiome and weight gain in children and adolescents","volume":"17","author":"Bretler T","year":"2019","unstructured":"Bretler T, Weisberg H, Koren O, Neuman H. The effects of antipsychotic medications on microbiome and weight gain in children and adolescents. BMC Med. 2019, 17:112. 10.1186\/s12916-019-1346-1","journal-title":"BMC Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2020.112886","article-title":"The gut microbiome and antipsychotic treatment response","volume":"396","author":"Seeman MV","year":"2021","unstructured":"Seeman MV. The gut microbiome and antipsychotic treatment response. Behav Brain Res. 2021, 396:112886. 10.1016\/j.bbr.2020.112886","journal-title":"Behav Brain Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2013.02.012","article-title":"SLC6A4 polymorphisms and age of onset in late-life depression on treatment outcomes with citalopram: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report","volume":"22","author":"Shiroma PR","year":"2014","unstructured":"Shiroma PR, Drews MS, Geske JR, Mrazek DA. SLC6A4 polymorphisms and age of onset in late-life depression on treatment outcomes with citalopram: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report. Am J Geriatr Psychiatry. 2014, 22:1140-8. 10.1016\/j.jagp.2013.02.012","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2015.27","article-title":"The BDNF gene Val66Met polymorphism as a modifier of psychiatric disorder susceptibility: progress and controversy","volume":"20","author":"Notaras M","year":"2015","unstructured":"Notaras M, Hill R, van den Buuse M. The BDNF gene Val66Met polymorphism as a modifier of psychiatric disorder susceptibility: progress and controversy. Mol Psychiatry. 2015, 20:916-30. 10.1038\/mp.2015.27","journal-title":"Mol Psychiatry"},{"key":"ref27","doi-asserted-by":"crossref","DOI":"10.1016\/j.eurpsy.2008.05.002","article-title":"Effect of COMT val158met genotype on cognition and personality","volume":"23","author":"Sheldrick A","year":"2008","unstructured":"Sheldrick A, Krug A, Markov V, et al.. Effect of COMT val158met genotype on cognition and personality. Eur Psychiatry. 2008, 23:385-9.","journal-title":"Eur Psychiatry"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1177\/1359786806066040","article-title":"The 5-HT2C receptor and antipsychotic induced weight gain - mechanisms and genetics","volume":"20","author":"Reynolds GP","year":"2006","unstructured":"Reynolds GP, Hill MJ, Kirk SL. The 5-HT2C receptor and antipsychotic induced weight gain - mechanisms and genetics. J Psychopharmacol. 2006, 20:15-8. 10.1177\/1359786806066040","journal-title":"J Psychopharmacol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2013.00024","article-title":"Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance","volume":"4","author":"Zanger UM","year":"2013","unstructured":"Zanger UM, Klein K. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front Genet. 2013, 4:24. 10.3389\/fgene.2013.00024","journal-title":"Front Genet"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.067660","article-title":"UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver","volume":"310","author":"Court MH","year":"2004","unstructured":"Court MH, Hao Q, Krishnaswamy S, Bekaii-Saab T, Al-Rohaimi A, von Moltke LL, Greenblatt DJ. UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver. J Pharmacol Exp Ther. 2004, 310:656-65. 10.1124\/jpet.104.067660","journal-title":"J Pharmacol Exp Ther"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2009.32","article-title":"Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome","volume":"10","author":"Laika B","year":"2010","unstructured":"Laika B, Leucht S, Heres S, et al.. Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. Pharmacogenomics J. 2010, 10:20-9. 10.1038\/tpj.2009.32","journal-title":"Pharmacogenomics J"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e3283385a1c","article-title":"Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)","volume":"21","author":"Hodges LM","year":"2011","unstructured":"Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz DL, Klein TE, Altman RB. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics. 2011, 21:152-61. 10.1097\/FPC.0b013e3283385a1c","journal-title":"Pharmacogenet Genomics"},{"key":"ref33","article-title":"Pre and post-natal risk and determination of factors for child obesity","volume":"9","author":"Trandafir LM","year":"2016","unstructured":"Trandafir LM, Temneanu OR. Pre and post-natal risk and determination of factors for child obesity. J Med Life. 2016, 9:386-91.","journal-title":"J Med Life"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2008.08.008","article-title":"Associations between body mass index and substance use disorders differ by gender: results from the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"34","author":"Barry D","year":"2009","unstructured":"Barry D, Petry NM. Associations between body mass index and substance use disorders differ by gender: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Addict Behav. 2009, 34:51-60. 10.1016\/j.addbeh.2008.08.008","journal-title":"Addict Behav"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12334","article-title":"Predicting adult obesity from childhood obesity: a systematic review and meta-analysis","volume":"17","author":"Simmonds M","year":"2016","unstructured":"Simmonds M, Llewellyn A, Owen CG, Woolacott N. Predicting adult obesity from childhood obesity: a systematic review and meta-analysis. Obes Rev. 2016, 17:95-107. 10.1111\/obr.12334","journal-title":"Obes Rev"},{"key":"ref36","article-title":"Psychotropic-induced weight gain and potential pharmacologic treatment strategies","volume":"2","author":"Gracious BL","year":"2005","unstructured":"Gracious BL, Meyer AE. Psychotropic-induced weight gain and potential pharmacologic treatment strategies. Psychiatry (Edgmont). 2005, 2:36-42.","journal-title":"Psychiatry (Edgmont)"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145712000399","article-title":"Critical review of antipsychotic polypharmacy in the treatment of schizophrenia","volume":"17","author":"Fleischhacker WW","year":"2014","unstructured":"Fleischhacker WW, Uchida H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int J Neuropsychopharmacol. 2014, 17:1083-93. 10.1017\/S1461145712000399","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2006.08.017","article-title":"Does antipsychotic polypharmacy increase the risk for metabolic syndrome?","volume":"89","author":"Correll CU","year":"2007","unstructured":"Correll CU, Frederickson AM, Kane JM, Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome?. Schizophr Res. 2007, 89:91-100. 10.1016\/j.schres.2006.08.017","journal-title":"Schizophr Res"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200009000-00009","article-title":"Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report","volume":"23","author":"Lerner V","year":"2000","unstructured":"Lerner V, Chudakova B, Kravets S, Polyakova I. Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report. Clin Neuropharmacol. 2000, 23:284-6. 10.1097\/00002826-200009000-00009","journal-title":"Clin Neuropharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/68799-synergistic-effects-of-psychotropics-leading-to-extraordinary-weight-gain","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:34:59Z","timestamp":1707507299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/68799-synergistic-effects-of-psychotropics-leading-to-extraordinary-weight-gain"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,14]]},"references-count":39,"URL":"https:\/\/doi.org\/10.7759\/cureus.17978","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,14]]}}}